Compounded Tirzepatide Marketing Claims, Checked Against FDA and FTC Rules

Released: November 9, 2026 · Last reviewed: November 9, 2026

We read 16 sellers’ own pages and checked their “same as Zepbound”, FDA, trial and guarantee wording against FDA and FTC rules.

Compounded tirzepatide is not FDA-approved and is not a generic. It is made with the drug in Zepbound, not the same product. That fact limits what a seller may truthfully say, and in 2025 and 2026 regulators started enforcing those limits in writing.

This piece sets out the rules, then checks the wording that 16 telehealth programs use on their own pages today. We quote exactly and date every read. A quote here is not a finding that a company broke the law; only FDA, the FTC or a court can decide that.

The rules, in plain terms

FDA: misbranding. Under section 502(bb) of the Food, Drug, and Cosmetic Act, "a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular." On September 9, 2025, FDA sent warning letters on that basis to telehealth sellers. It cited Remedy Meds for "Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound" and Lyfe Rx for "Clinically Proven Weight Loss." Each letter says: "Compounded drug products are not FDA-approved."

On March 3, 2026, FDA announced 30 more letters, its second group to telehealth firms, aimed at "claims implying sameness with FDA-approved products." Its guidance page for telehealth companies, current as of June 15, 2026, lists five claims it calls false or misleading:

• describing a compounded drug "as a generic version of an FDA-approved drug or the same as a drug approved by FDA";
• claiming it "has been FDA-approved or has otherwise been evaluated for safety and effectiveness";
• describing it "as clinically proven to produce the same result as the FDA-approved drug";
• claiming it is "sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility";
• branding that implies the telehealth company is the compounder.

FDA's consumer page on unapproved GLP-1 drugs, current as of October 1, 2026, lists as a red flag a company that "makes claims such as the compounded drug is the same as an FDA-approved drug."

FTC: deception and proof. Section 5 of the FTC Act bars deceptive practices. The FTC's health-products guidance requires "competent and reliable scientific evidence" for health claims and asks: "How do the dosage and formulation of the advertised product compare to the product used in the study?" It adds that dramatic testimonials are "likely to be deceptive," and that "Results not typical" does not cure them. The FTC's guarantee guides say "Money Back Guarantee" should be used only if the seller "refunds the full purchase price," with "any material limitations or conditions" disclosed clearly.

Industry review. On November 4, 2026, BBB National Programs' advertising division ruled on Lilly's challenge to Good Life Meds. It found the tirzepatide studies "largely concerned Lilly's FDA-approved products" and did not support claims about the compounded product. A March 2026 court order in Lilly's suit against Fella Health reasoned that a competitor generally cannot sue just because a results claim is unproven. Our enforcement tracker follows the letters.

Claim by claim

"Same as Zepbound" and "same active ingredient"

FDA has cited "same active ingredient" wording in letters from September 2025 through February 2026. We did not find that phrase on any page we read today. SnagRx came closest: "These are the same medications that people are talking about all over the country." NexLife and Mondae state the opposite in plain words.

"FDA-approved," "FDA-registered," "FDA-regulated"

No page we read called compounded tirzepatide FDA-approved. Softer wording remains. MEDVi, Embody and SnagRx share one sentence: "Compounded GLP-1s are produced in FDA-regulated facilities." Eden's homepage lists "FDA-registered labs." NexLife's FAQ says "certain formulations are sourced from FDA-registered 503B outsourcing facilities," which does not match its plan pages; those name three state-licensed 503A pharmacies. Registration is a real status for 503B facilities, but it is not approval; see our legality explainer.

"Clinically proven" and trial percentages

Trial figures come from Lilly's product. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand). In SURMOUNT-5, tirzepatide averaged 20.2% versus 13.7% for semaglutide. Mochi cites the 20.9% figure and footnotes the trial. NexLife's FAQ says "up to 24.3%" for SURMOUNT-1 at 72 weeks; the trial's published 15 mg mean is 20.9%, and we could not match 24.3% to it. Henry Meds' page states the opposite principle: trial data on approved drugs "should not be used to make assessments related to compounded medications."

"Generic"

No page we read called its product generic. Mondae's disclaimer says its medications "are not generic versions of, therapeutically equivalent to, or substitutes for" approved drugs.

"Lose X% or your money back"

This is where the pages differ most, so the full table matters.

Claims audit, November 2026

NexLife's own pages do not agree with each other. Its FAQ advertises "lose up to 10%" or "your money back." Its refund policy pays back program and membership fees, not medication, and only if a member loses less than 5% over six months while meeting conditions: enrolled on or after January 1, 2026, 180 straight days, no refill gaps, weight logged at least every two weeks, starting BMI of 30 or more, and a claim filed between day 181 and day 210. The plan page we read today shows no guarantee banner. Our NexLife review quotes the policy page.

What this means for you

Treat every claim as a question to ask, not an answer. Three checks take five minutes.

1. Find the basis for any percentage. Is it Lilly's trial, a company survey, or self-reported weights? Found's page shows both 16% and 12%; ask which applies to the product you would buy.
2. Read the guarantee terms, not the banner. Note the threshold, the time window, what is refunded and the claim deadline.
3. Look for the FDA line. A page should say plainly that compounded tirzepatide is not FDA-approved. "FDA-registered" or "FDA-regulated" describes a facility, not your medication.

Worked examples

What a guarantee threshold means. Start at 220 lb. Five percent is 11 lb; 10% is 22 lb; 15% is 33 lb. Under NexLife's policy you could claim only if you lost less than 11 lb in six months. Under Eden's banner, losing less than 33 lb in six months may qualify; we did not read Eden's full terms.

What a guarantee pays. NexLife's policy gives its own example: about $250 of $834 paid over six months, roughly 30%. At today's 6-month price of $119 a month, you would pay $714; the policy does not state the refundable share at that price.

What the trial number means. At 20.9%, a 220-lb person would lose about 46 lb, but over 72 weeks on Lilly's 15 mg dose, not six months on a compounded version. Nobody can promise you that result.

What a year costs. NexLife's compounded tirzepatide is $129 month to month as of November 6, 2026, or $1,548 a year; its 12-month plan totals $1,380. Eden listed $129 a month on October 15, 2026, the same as NexLife's month-to-month price. Brand Zepbound at $449 a month, the 7.5–15 mg self-pay price with refills within 45 days, costs $5,388 a year, $3,840 more than $1,548. Compare current prices in our pricing database and the brand route in our Zepbound cost guide.

We re-read these pages on a schedule; our methodology explains how quotes and dates are logged.

Frequently asked questions

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is made with the drug in Zepbound, but it is not the same product. It is not FDA-approved, FDA does not review it for safety, effectiveness or quality before sale, and it is not a generic. FDA has sent warning letters over "same active ingredient" wording because it implies sameness with an approved drug. Your prescriber can explain why a compounded version was chosen for you.

Can a telehealth company say its pharmacy is FDA-approved?

FDA lists claiming a compounded drug "is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility" as false or misleading. Some facilities, called 503B outsourcing facilities, register with FDA, so "FDA-registered" can be accurate for them. Registration is not approval of the drug. On November 9, 2026, three programs used "FDA-regulated" and two used "FDA-registered" wording on the pages we read.

Are "lose X% or your money back" guarantees real?

They are offers with conditions. The FTC's guides say "Money Back Guarantee" should mean a full refund, with material limits disclosed clearly. Read the terms: the weight threshold, the time window, logging rules, what is refunded and the claim deadline. NexLife's policy, for example, refunds program fees but not medication, and only below 5% loss over six months.

Why do sites quote 20.9% weight loss?

Those numbers come from SURMOUNT-1, Lilly's 72-week trial of its own tirzepatide. The 15 mg dose averaged 20.9% under the treatment-regimen estimand. The trial did not test compounded products, and the FTC asks whether a study's dosage and formulation match the advertised product. A trial figure tells you what Lilly's drug did, not what a compounded version will do for you.

How did we audit these claims?

On November 9, 2026, we requested each program's tirzepatide or main weight-loss page with a standard browser request and searched the served text for sameness, FDA, proof, generic and guarantee wording. We recorded short exact quotes. We did not read images, quizzes or checkout pages, so "none found" means none in the text we read. TrimRx served no readable text, and Embody's product page blocked us.

Sources

1. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs (U.S. Food and Drug Administration, content current as of June 15, 2026; read November 2026)
2. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (U.S. Food and Drug Administration, March 3, 2026; read November 2026)
3. Warning Letter 716830: Remedy Meds (U.S. Food and Drug Administration, September 9, 2025; read November 2026)
4. Warning Letter: Lyfe Rx (U.S. Food and Drug Administration, September 9, 2025; read November 2026)
5. Warning Letter 721446: BluefitMD (U.S. Food and Drug Administration, February 20, 2026; read November 2026)
6. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration, content current as of October 1, 2026; read November 2026)
7. Health Products Compliance Guidance (Federal Trade Commission, 2022; read November 2026)
8. 16 CFR Part 239: Guides for the Advertising of Warranties and Guarantees (Federal Trade Commission via eCFR, current text; read November 2026)
9. NAD Case #7586: Good Life Meds, LLC (BBB National Programs, November 4, 2026; read November 2026)
10. Eli Lilly v. Aios Inc. (Fella Health and Delilah), Order on Motion to Dismiss (U.S. District Court, N.D. Cal., March 26, 2026; read November 2026)
11. Tirzepatide Once Weekly for the Treatment of Obesity: SURMOUNT-1 (American College of Cardiology, 2022; read November 2026)
12. Nexlife Refund Policy (NexLife, undated page; read November 2026)
13. Frequently Asked Questions (NexLife, undated page; read November 2026)
14. GLP-1 Weight Loss (Eden, undated page; read November 2026)